Clinical experience of galantamine in dementia: a series of case reports

References

• Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20:736–48
   PubMed Web of Science ®Google Scholar
• Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. Psychol Med 1998;28:319–35
   Google Scholar
• Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160 (Suppl):SI-S15
   Google Scholar
• McNamee E, Bond J, Buck D. Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001;179:261–6
   PubMed Web of Science ®Google Scholar
• Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's dis-ease. Am J Psychiatry 1990;147:1049–51
   PubMed Web of Science ®Google Scholar
• Morriss RK, Rovner BW, German PS. Factors contributing to nursing home admission because of disruptive behaviour. Int J Geriatr Psychiatry 1996;11:243–9
   Web of Science ®Google Scholar
• Gallagher M, Colombo PJ. Aging: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995;5:161–8
   PubMed Web of Science ®Google Scholar
• Kasa P Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511–35
   PubMed Web of Science ®Google Scholar
• Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000;113:199–206
   PubMed Web of Science ®Google Scholar
• Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653–66
   PubMed Web of Science ®Google Scholar
• Christie JE, Shering A, Ferguson J, Glen AT. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer pre-senile dementia. Br J Psychiatry 1981;138:46–50
   PubMed Web of Science ®Google Scholar
• Little A, Levy R, Chuaqui-Kidd E Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's dis-ease. J Neurol Neurosurg Psychiatry 1985;48;736–42
   PubMed Web of Science ®Google Scholar
• Byrne GJA. Treatment of cognitive impairment in Alzheimer's disease. Aust J Hosp Pharm 1998;28:261–6
   Google Scholar
• Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 1995;4:349–56
   PubMedGoogle Scholar
• Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996;103:1211–20
   PubMed Web of Science ®Google Scholar
• Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-) galan-thamine at 2.3 A resolution. FEBS Lett 1999;463: 321–6
   PubMed Web of Science ®Google Scholar
• Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, et al. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur J Pharmacol 1995;290:207–19
   PubMed Web of Science ®Google Scholar
• Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a ran-domised, controlled trial. J Neurol Neurosurg Psych 2000;71:589–95
   Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfield S, et al. A 5-month randomized, placebo-controlled trial of galanta-mine in AD. Neurology 2000;54:2269–76
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lileinfeld S, Gaens E. Efficacy and safety of galan-tamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine Interantional-1 Study Group. BMJ 2000;321: 1445–9
   PubMed Web of Science ®Google Scholar
• Rockwood K, Graham JE, Fay S. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002;73:500–7
   PubMed Web of Science ®Google Scholar
• Mohs RC, Ferris SH. Measuring response to treatment in Alzheimer's disease: what constitutes meaningful change? Int J Geriatr Psychopharmacol 1998;1 (Suppl):S7–S14
   Google Scholar
• Gold L, Rayner I. Dealing with dementia. Pulse 2002;25:52–5
   Google Scholar
• Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001;18:853–62
   PubMed Web of Science ®Google Scholar
• Rosler M, Anand R, Cicin-Sain A, Gauthiers S, Agid Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633–60
   PubMed Web of Science ®Google Scholar
• Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerabili-ty of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin Ther 2001;23 (Suppl A):A25–A30
   Google Scholar
• Maelicke A. Pharmacolcinetic rationale for switching from donepezil to galantamine. Clin Ther 2001;23 (Suppl A):A8-Al2
   PubMedGoogle Scholar
• Snorrason E, Stefansson JG. Galantamine hydrobromide in mania. Lancet 1991;337:557
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, et al. A randomised trial of risperidone, place-bo, and haloperidol for behavioural symptoms of dementia. Neurology 1999;53:946–55
   PubMed Web of Science ®Google Scholar
• Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, et al. Comparison of risperidone and placebo for psychosis and behav-ioural disturbances associated with dementia: a randomised, dou-ble-blind trial. J Clin Psychiatry 1999;60:107–15
   PubMed Web of Science ®Google Scholar
• Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl"). Int J Clin Pract 2001;120 (Suppl):24–8
   Web of Science ®Google Scholar
• Erlcinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283–90
   PubMed Web of Science ®Google Scholar
• McKeith TG, Del Ser T, Spano P, Emre M, Wesnes K, et al Efficacy of rivastigmine in dementia with Lewy bodies: a ran-domised, double-blind, placebo controlled international study. Lancet 2000;356:2031–6
   PubMed Web of Science ®Google Scholar
• Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficiency in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516–19
   PubMed Web of Science ®Google Scholar
• Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229–38
   PubMedGoogle Scholar
• MacLean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 2001;13:277–88
   PubMed Web of Science ®Google Scholar
• Teri L, Borson S, Kiyak HA, Yamagashi M. Behavioural distur-bance, cognitive dysfunction and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109–16
   PubMed Web of Science ®Google Scholar
• Brodaty H, McGilchrist C, Harris L, Peters K. Time until insti-tutionalisation and death in patients with dementia. Arch Neurol 1993;50:643–50
   PubMed Web of Science ®Google Scholar